Pyrrolomycin group antibiotics inhibit substance P-induced release of myeloperoxidase from human polymorphonuclear leukocytes.
In order to search for microbial modulators of the activity of neuropeptide, we established a screen based on substance P (SP)-induced myeloperoxidase (MPO) release from human polymorphonuclear leukocytes (PMN). SP induced MPO release in a dose-dependent manner at concentrations ranging from 1 approximately 10 x 10(-4) M. In comparison at 1 x 10(-4) M, induction was also observed with SP derivatives but not with other neuropeptides such as neurokinin and enkephalin. Based on this, we searched for microbial inhibitors against SP-induced MPO release. An actinomycete metabolite designated HS3, which turned out to be identical with dioxapyrrolomycin or A1-R2081, and structurally related pyrrolomycins were found to inhibit SP-induced MPO release. In addition, these compounds inhibited the f-Met-Leu-Phe (FMLP)-induced MPO release from PMN. Pyrrolomycin derivatives with an N-methylated pyrrole ring showed, however, a selective inhibition of the SP-induced MPO release. This was in contrast to results with aseanostatin P5 which selectively inhibited FMLP-induced MPO release.
Masuda
K
K
Department of Antibiotics, National Institute of Health, Tokyo, Japan.
Suzuki
K
K
Ishida-Okawara
A
A
Mizuno
S
S
Hotta
K
K
Miyadoh
S
S
Hara
O
O
Koyama
M
M
D000192:Actinomycetales / Q000378:metabolism; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009504:Neutrophils / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D009195:Peroxidase / Q000097:blood / Q000378:metabolism*; D011758:Pyrroles / Q000494:pharmacology; D013373:Substance P / Q000037:antagonists & inhibitors*
D000900:Anti-Bacterial Agents; D011758:Pyrroles; C053531:pyrroxamycin; D013373:Substance P; D009195:Peroxidase